Pasireotide versus octreotide in acromegaly: A head-to-head superiority study

A. Colao, M. D. Bronstein, P. Freda, F. Gu, C. C. Shen, M. Gadelha, Maria Fleseriu, A. J. Van Der Lely, A. J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, M. Sheppard

Research output: Contribution to journalArticle

197 Scopus citations


Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical control. Objective: Our objective was to demonstrate the superiority of pasireotide LAR over octreotide LAR in medically naive patients with acromegaly. Design and Setting: We conducted a prospective, randomized, double-blind study at 84 sites in 27 countries. Patients: A total of 358 patients with medically naive acromegaly (GH >5 μg/L or GH nadir ≥1 μg/L after an oral glucose tolerance test (OGTT) and IGF-1 above the upper limit of normal) were enrolled. Patients either had previous pituitary surgery but no medical treatment or were de novo with a visible pituitary adenoma on magnetic resonance imaging. Interventions: Patients received pasireotide LAR 40 mg/28 days (n = 176) or octreotide LAR 20 mg/28 days (n = 182) for 12 months. At months 3 and 7, titration to pasireotide LAR 60 mg or octreotide LAR 30 mg was permitted, but not mandatory, if GH ≥2.5μg/L and/or IGF-1 was above the upper limit of normal. Main Outcome Measure: The main outcome measure was the proportion of patients in each treatment arm with biochemical control (GH

Original languageEnglish (US)
Pages (from-to)791-799
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Issue number3
Publication statusPublished - 2014
Externally publishedYes


ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Colao, A., Bronstein, M. D., Freda, P., Gu, F., Shen, C. C., Gadelha, M., ... Sheppard, M. (2014). Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism, 99(3), 791-799.